Aurinia Pharmaceuticals Inc. (AUPH)
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises
AUPH settles voclosporin patent litigation with Teva, delaying potential generic competition in the United States until December 2036.
Aurinia Pharmaceuticals Doubles Down On Its Pipeline
Aurinia Pharmaceuticals is running the phase 4 PRESERVE trial in lupus nephritis, which tests combinations containing the company's drug Lupkynis. Lupkynis could face potential challenges to its market exclusivity in the not-too-distant future. AUPH is developing aritinercept in four potential indications but doesn't provide much clarity on timelines for further updates.
Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates
Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.16 per share a year ago.
Aurinia (AUPH) Upgraded to Strong Buy: Here's Why
Aurinia (AUPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Aurinia (AUPH) Moves 6.5% Higher: Will This Strength Last?
Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Aurinia: Cash-Generating Today, Pipeline-Driven Tomorrow
Aurinia Pharmaceuticals (AUPH) is positioned for profitable growth, driven by Lupkynis and pipeline expansion via the Kezar Life Sciences acquisition. AUPH delivered strong 1Q26 results: 24% revenue growth, 48% net income growth, and robust cash flow, reaffirming FY26 guidance for double-digit revenue gains. Tang Capital Management increased its stake above 10%, signaling confidence in AUPH's valuation and future pipeline or strategic optionality.
Aurinia Pharmaceuticals (AUPH) Q1 Earnings and Revenues Top Estimates
Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.16 per share a year ago.
Aurinia Pharmaceuticals: New Management, Continued Lupkynis Performance
Aurinia Pharmaceuticals has undergone a major management overhaul, with fund manager and activist investor Kevin Tang appointed as the CEO. AUPH's COO and CFO have also been replaced. Lupkynis's net product sales reached $271.3M in 2025, up 25.5% YoY, with 2026 guidance for $305M–$315M, possibly conservative given the company's previous beat of initial 2025 guidance. Aritinercept will be evaluated in two autoimmune diseases, with one clinical study already underway and another set to commence in H1 2026, although the exact indications have not been disclosed.
Aurinia Pharmaceuticals Inc. (AUPH) Q4 2025 Earnings Call Transcript
Aurinia Pharmaceuticals Inc. (AUPH) Q4 2025 Earnings Call Transcript
Aurinia Pharmaceuticals (AUPH) Tops Q4 Earnings and Revenue Estimates
Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.09 per share a year ago.
Is Aurinia Pharmaceuticals (AUPH) Outperforming Other Medical Stocks This Year?
Here is how Aurinia Pharmaceuticals (AUPH) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year?
Here is how Aurinia Pharmaceuticals (AUPH) and Cardinal Health (CAH) have performed compared to their sector so far this year.
